Source link : https://newshealth.biz/health-news/t-dxd-prevails-in-trial-of-second-line-therapies-for-her2-gastroesophageal-cancer/
(MedPage Today) — CHICAGO — Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115823 Author : Publish date : 2025-05-31 12:00:00 Copyright for syndicated content belongs to the linked Source.
The post T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-31 12:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8